Lantheus posts Q3 2026 results and pauses guidance amid pending merger
Lantheus Holdings reported third‑quarter 2026 revenue of $389.9 million, a 1.5% year‑over‑year increase, and GAAP diluted earnings of $0.33 per share. Adjusted diluted EPS rose to $1.68, beating expectations, while net income fell to $22.4 million. The company announced FDA approvals for TAUKLARIFY and BRAVNETSA and said it is suspending its 2026 financial guidance while a merger with Curium US Holdings proceeds, under which Curium will pay $102.50 in cash per share at closing and may issue additional contingent value rights worth up to $12.00 per share.
Why it matters
The suspension of guidance leaves investors without forward‑looking financial targets until the merger closes, increasing uncertainty about future performance. The agreed acquisition price of $102.50 per share, plus potential CVR payments, defines the valuation that shareholders will receive if the deal is completed.
Key facts
- 1Third‑quarter 2026 revenue was $389.9 million, up 1.5% YoY. tradingview.com
- 2GAAP diluted earnings per share for the quarter were $0.33. tradingview.com
- 3Adjusted diluted EPS increased to $1.68 from $1.27 a year earlier. tradingview.com
- 4Net income for the quarter was $22.4 million, down from $27.8 million in the prior year quarter. tradingview.com
- 5The FDA approved TAUKLARIFY and BRAVNETSA during the quarter. tradingview.com
- 6Curium US Holdings will acquire Lantheus for $102.50 cash per share at closing, with optional CVRs that could add up to $12.00 per share based on commercial milestones. tradingview.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.